Abcuro, Inc. raises $66 million in Series D financing led by New Leaf Venture Partners to advance its first-in-class medicine for Inclusion Body Myositis.
Amount Raised
$66 Million
Round Type
Series D
NewtonvilleBiotechnologyHealth CareTherapeuticsInvestors
Description
Abcuro, Inc. has successfully closed a $66 million Series D financing. The round was led by New Leaf Venture Partners, with participation from existing investors including abrdn Inc., Bain Capital Life Sciences, and others. The funds will be used to advance its medicine in development for Inclusion Body Myositis
Quick answer
Abcuro raised $66 Million in a Series D round, dated August 18, 2026. Investors: Bain Capital Life Sciences, Abrdn Inc., Redmile Group, Samsara Biocapital, Mass General Brigham Ventures, RA Capital and New Leaf Venture Partners. Abcuro is based in Newtonville, Massachusetts, United States.
- How much did Abcuro raise?
- Abcuro raised $66 Million in a Series D round on August 18, 2026.
- Who invested in Abcuro?
- Bain Capital Life Sciences, Abrdn Inc., Redmile Group, Samsara Biocapital, Mass General Brigham Ventures, RA Capital and New Leaf Venture Partners are named as investors in this round.
- What does Abcuro do?
- Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer..
- Where is Abcuro based and how big is it?
- Abcuro is based in Newtonville, Massachusetts, United States.
- Who are the decision-makers at Abcuro?
- Fundz holds 2 contacts at Abcuro, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Abcuro that raised within 45 days of this round, from Fundz verified event records.
- Ensho Therapeutics raised $7.3M on October 2, 2026.
- Omnio raised $3.3M (Seed) on October 2, 2026.
- R1 Therapeutics raised $81M (Series A) on September 30, 2026.
- Breye Therapeutics raised $77M (Series A) on September 29, 2026.
- Aptadir Therapeutics raised $45M (Seed) on September 29, 2026.
- Link Cell Therapies raised $30M (Series A) on September 28, 2026.
Who to call at Abcuro, and when
A new round usually means Abcuro is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Abcuro raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Abcuro, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Abcuro. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Abcuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Abcuro raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.